Ipilimumab (Yervoy)
A CTLA-4 checkpoint inhibitor immunotherapy for melanoma, kidney cancer, liver cancer, lung cancer, and other solid tumours.
What is Ipilimumab?
What it targets
The CTLA-4 checkpoint on T cells, which normally prevents excessive immune activation. Blocking CTLA-4 removes this inhibitory brake, allowing T cells to proliferate and attack tumours.
Who it may help
Patients with unresectable or metastatic melanoma, advanced renal cell carcinoma, non-small cell lung cancer, hepatocellular carcinoma, mesothelioma, MSI-H/dMMR colorectal cancer, or esophageal cancer.
Why testing matters
Baseline blood tests, liver and kidney function, and imaging confirm cancer extent. PD-L1 testing can help guide combination decisions. Immune history and prior autoimmune disease assessment are essential before starting treatment.
Which cancers can ipilimumab treat?
Ipilimumab is approved or used across several cancer types, often in combination with nivolumab for improved outcomes.
| Melanoma (unresectable/metastatic) | FDA-approved as single agent or with nivolumab for all patients. Combination nivolumab/ipilimumab is preferred first-line per NCCN 2026. |
| Melanoma (adjuvant) | Approved for stage III melanoma with nodal involvement after complete resection. Extended dosing improves recurrence-free survival. |
| Renal cell carcinoma (RCC) | Combined with nivolumab for intermediate/poor-risk metastatic RCC. Preferred first-line regimen improving progression-free survival. |
| Non-small cell lung cancer (NSCLC) | With nivolumab for first-line metastatic/recurrent NSCLC without EGFR/ALK mutations. Also used with nivolumab and platinum chemotherapy. |
| Hepatocellular carcinoma (HCC) | With nivolumab for first-line unresectable/metastatic HCC. CheckMate-9DW showed improved median OS and higher response rates. |
| Mesothelioma (malignant pleural) | With nivolumab for first-line unresectable disease. First systemic approval for mesothelioma in 16 years. |
| Colorectal cancer (MSI-H/dMMR) | With nivolumab for unresectable/metastatic MSI-H or dMMR CRC. CHECKMATE-8HW approved April 2025 with strong PFS benefit. |
| Esophageal squamous cell carcinoma | With nivolumab for first-line unresectable advanced or metastatic disease with PD-L1 expression >= 1%. |
Are you eligible for ipilimumab?
Eligibility depends on cancer type, stage, organ function, and immune history. Ipilimumab requires careful patient selection and monitoring.
- Confirmed diagnosis of approved cancer type: melanoma, RCC, NSCLC, HCC, mesothelioma, MSI-H/dMMR CRC, or ESCC.
- Metastatic, unresectable, or recurrent disease in most settings; or high-risk resected disease in adjuvant melanoma.
- Adequate organ function: ECOG performance status 0-1; normal liver, kidney, and thyroid function at baseline.
- No active autoimmune disease such as lupus, rheumatoid arthritis, inflammatory bowel disease, or active hepatitis.
- No prior organ transplant or stem cell transplant unless specifically approved by your oncology team.
- Ability to tolerate monitoring: frequent blood tests and imaging scans to assess response and detect immune toxicity.
- Willing to use effective contraception if of childbearing potential; ipilimumab causes foetal harm.
How does ipilimumab work?
- Blocking CTLA-4
- T-cell activation and expansion
- Immune attack on tumour cells
- Durable immune memory
Ipilimumab can trigger durable, long-lasting cancer control by permanently boosting anti-tumour immunity.
Tests required before starting ipilimumab
These tests establish baseline health, confirm eligibility, and allow your team to detect immune-related side effects early.
| Complete blood count (CBC) | Baseline white blood cell, red blood cell, and platelet counts. Monitored during treatment for immune-related changes. |
| Liver function tests (LFTs) | AST, ALT, bilirubin, albumin. Critical baseline for detecting immune hepatitis, which can develop during ipilimumab treatment. |
| Kidney function (creatinine, eGFR) | Baseline creatinine and estimated glomerular filtration rate. Ipilimumab can rarely cause immune nephritis. |
| Thyroid function (TSH, free T4) | Baseline assessment. Ipilimumab can cause hypothyroidism or hyperthyroidism in 10-15% of patients. |
| Imaging (CT, PET-CT, or MRI) | Establishes baseline tumour burden, location, and extent. Repeated periodically to assess response. |
| Pathology review and histology | Confirms cancer diagnosis and histological type. Required for treatment planning and biomarker assessment. |
How is ipilimumab given?
Ipilimumab is administered as an intravenous infusion in a hospital or infusion centre. Dosing depends on indication and whether it is used alone or with other agents.
| Melanoma (single agent) | 3 mg/kg intravenously over 30 minutes every 3 weeks for 4 doses. Total treatment duration about 12 weeks. |
| Melanoma (adjuvant) | 10 mg/kg intravenously over 90 minutes every 3 weeks for 4 doses, then 10 mg/kg every 12 weeks for up to 3 years. |
| With nivolumab (combination) | 3 mg/kg ipilimumab + 1 mg/kg nivolumab on same day, every 3 weeks for 4 doses, then nivolumab monotherapy. |
| With nivolumab and chemotherapy | Nivolumab first, then ipilimumab, then 2 cycles platinum-doublet chemotherapy on same day, every 3 weeks. |
| Administration details | Infusion over 30 minutes unless otherwise specified. Given in a hospital setting with monitoring for infusion reactions. |
| Duration of treatment | Induction phase typically 4 doses over 12 weeks. Maintenance therapy with nivolumab continues until disease progression or unacceptable toxicity. |
Clinical evidence and benefits
Ipilimumab offers durable survival benefit, particularly in combination with nivolumab for multiple cancer types.
| Melanoma survival | Single-agent and combination regimens produce substantially improved overall survival compared to chemotherapy, with median OS reaching 24+ months in many patients. |
| RCC first-line combination | Nivolumab plus ipilimumab superior to sunitinib in intermediate/poor-risk RCC. Median PFS significantly improved with durable responses. |
| HCC first-line efficacy | CheckMate-9DW: median OS 23.7 months with nivolumab/ipilimumab vs 20.6 months with lenvatinib/sorafenib (p<0.02). |
| NSCLC response rates | Combination regimens in lung cancer achieve higher objective response rates compared to single-agent checkpoint inhibition. |
| Mesothelioma control | Combination therapy significantly extends progression-free survival in unresectable disease, with majority of patients achieving disease control. |
| Colorectal cancer breakthrough | MSI-H/dMMR CRC: median PFS not reached with nivolumab/ipilimumab vs 5.8 months with chemotherapy (p<0.0001, April 2025 approval). |
Individual responses vary significantly. These results represent pivotal clinical trial outcomes in eligible patients.
Side effects of ipilimumab
Ipilimumab causes immune-related adverse events (irAEs) where the activated immune system can attack normal tissues. Most are manageable with early recognition and corticosteroid treatment.
| Fatigue | Very common (>50% of patients). Usually mild to moderate; improves with rest and supportive care. |
| Diarrhea | Common (>30%). Can progress to severe immune colitis requiring urgent intervention; monitor closely. |
| Rash and pruritus | Very common (>30%). Often mild; manage with topical steroids or antihistamines; severe rash requires systemic treatment. |
| Nausea and loss of appetite | Common (20-30%). Usually manageable with anti-nausea medications and dietary adjustment. |
| Immune hepatitis | Occurs in 10-15%; can be severe. Requires baseline LFTs and repeat monitoring; managed with corticosteroids. |
| Hypothyroidism | Occurs in 10-15%, occasionally hyperthyroidism. Managed with thyroid hormone replacement or beta-blockers. |
| Immune pneumonitis | Rare but serious (1-5%). Presents as cough, dyspnoea; requires corticosteroids and sometimes immunosuppression. |
| Endocrinopathies | Hypopituitarism, adrenal insufficiency, type 1 diabetes can develop. Monitor hormone levels; hormone replacement often needed. |
Contact your doctor immediately if you develop:
- Severe or bloody diarrhea, severe abdominal pain, or inability to eat.
- Yellowing of eyes or skin, dark urine, abdominal pain, or signs of liver injury.
- New or worsening shortness of breath, chest pain, or persistent cough.
- Severe rash, blistering, peeling skin, or signs of Stevens-Johnson syndrome.
- Severe headache, confusion, vision changes, dizziness, or fainting.
Safety precautions and drug interactions
Tell your oncologist and pharmacist about all medicines, supplements, and medical history before starting ipilimumab.
- Autoimmune disease: lupus, rheumatoid arthritis, inflammatory bowel disease, myasthenia gravis, psoriasis.
- Prior organ transplant or stem cell transplant (relative contraindication; specialist consultation required).
- Hepatitis B, hepatitis C, HIV, or tuberculosis: increased risk of reactivation.
- Pregnancy or breastfeeding: ipilimumab causes foetal harm; contraception required; no breast feeding.
- Current immunosuppressive therapy: corticosteroids, TNF inhibitors may interfere with ipilimumab effect.
- Drug interactions: vemurafenib and leflunomide may increase hepatotoxicity when combined with ipilimumab.
- Live vaccines contraindicated during and for some time after ipilimumab (inactivated vaccines are safe).
Ipilimumab combination treatments
Ipilimumab is most potent when combined with nivolumab, another checkpoint inhibitor. Combinations produce higher response rates than monotherapy but with increased immune toxicity.
| Nivolumab + ipilimumab | Preferred first-line for melanoma, RCC, HCC, mesothelioma, MSI-H/dMMR CRC. Significantly improves response rates and survival vs monotherapy. |
| Nivolumab + ipilimumab + chemotherapy | First-line for NSCLC without EGFR/ALK mutations. 2 cycles of platinum-doublet chemotherapy added for rapid control. |
| Single-agent ipilimumab | Used alone in melanoma when nivolumab is contraindicated or unavailable. Lower response rate than combination but acceptable tolerability profile. |
| Switching options if intolerance | If ipilimumab toxicity is unmanageable, may switch to BRAF/MEK inhibitors (melanoma), TKIs (RCC, NSCLC), or other targeted therapy depending on biomarkers. |
| Sequential immunotherapy | If ipilimumab progresses, can switch to different checkpoint inhibitor or targeted therapy. Treatment choice guided by mechanism of resistance. |
If ipilimumab stops working
Some patients' cancers progress during or after ipilimumab. Understanding resistance mechanisms guides next-line options.
| Primary and acquired resistance | Primary: no response from start. Acquired: response followed by progression. Both may reflect immune evasion or selection of resistant clones. |
| Resistance mechanisms | Loss of T-cell infiltration, upregulation of other checkpoints (LAG-3, TIM-3), dysfunction of antigen-presenting cells, tumour microenvironment changes. |
| Managing progression | Repeat imaging to confirm true progression vs pseudoprogression. Consider liquid biopsy or repeat biopsy. NGS testing identifies targetable mutations (BRAF, KIT, EGFR, ALK, etc.). |
| Switch to targeted therapy | If biomarker-driven resistance identified: BRAF/MEK for melanoma, tyrosine kinase inhibitors for RCC/NSCLC, ALK/ROS1 inhibitors if applicable. |
| Other immunotherapy approaches | LAG-3 inhibitors, TIM-3 pathway inhibitors, and other checkpoint combinations under clinical trial investigation. |
Cost of ipilimumab by country
Ipilimumab is expensive; no generics exist. Costs vary by country, regimen, and availability of patient assistance programmes.
| India | Not approved for marketing. Named patient import: Rs. 60,000-1,05,000 per vial; specialist hospital markup may apply. Import permits required. |
| USA | Brand name only (Yervoy); no generics or biosimilars available. Out-of-pocket costs high; insurance coverage varies. Bristol-Myers Squibb patient assistance available. |
| UK/Europe | NHS/national insurance coverage varies by country. Approved in most European Union countries; reimbursement subject to health authority decisions. |
| China | Available through major cancer hospitals; pricing negotiable. Often more affordable than Western prices. Regulatory approval in major cities. |
Availability of ipilimumab globally
Ipilimumab is widely approved and accessible in developed markets and major cancer centres, with variable access in other regions.
India
Not approved for marketing. Available through named patient import programmes and specialist hospitals. Requires valid prescription, diagnostic reports, and import permit. Access facilitated through pharmaceutical facilitators.
USA
FDA-approved since 2011. Available as Yervoy in hospitals and infusion centres nationwide. Covered by major insurers; patient assistance programmes available through manufacturer for uninsured/underinsured.
UK/Europe
EMA-approved. Available through NHS in UK and national health systems in EU countries. Subject to local reimbursement decisions; generally available in major cancer centres.
China
NMPA-approved for multiple indications. Widely available in major cancer hospitals in Beijing, Shanghai, Guangzhou, and other tier-1 cities. Cost typically lower than USA; rapid access at specialized centres.
Southeast Asia
Available in Singapore, Thailand, Vietnam through approved cancer centres. Regulatory status varies; some countries via special import programmes. CancerFax can help identify access routes.
Ipilimumab in current clinical trials
Ongoing trials explore newer combinations, earlier-line use, resistant disease, and refinement of patient selection.
| Combination with LAG-3 inhibitors | Phase 3 trials exploring dual-checkpoint blockade (CTLA-4 + LAG-3) for melanoma and other solid tumours. |
| Neoadjuvant approaches | Studies in resectable high-risk melanoma and other cancers; goal is pathological complete response before surgery. |
| Biomarker-stratified trials | Research into CTLA-4 density, tumour mutational burden (TMB), and immune infiltration to predict ipilimumab benefit. |
| Resistance and re-challenge | Trials examining ipilimumab rechallenge in patients with prior response and subsequent progression. |
Your treatment journey with ipilimumab
Diagnosis and staging
Biomarker and organ function assessment
Consultation and treatment planning
Starting treatment
Ongoing monitoring during induction
Maintenance and follow-up
If progression or intolerance
Questions to ask your oncologist about ipilimumab
- Is ipilimumab appropriate for my cancer stage and type?
- Will I receive ipilimumab alone or in combination with other drugs?
- What response can I realistically expect?
- What are the most common immune side effects I should watch for?
- How often will I need imaging and blood tests?
- What happens if ipilimumab does not work or stops working?
- Can ipilimumab be given near my home, or do I need to travel?
- What is the estimated total cost of treatment and what financial assistance is available?
How CancerFax supports ipilimumab patients
CancerFax helps patients navigate ipilimumab access, side effect management, and advanced treatment planning.
| Medical record review | Upload pathology, imaging, and treatment reports. CancerFax medical team reviews and explains what findings mean for ipilimumab eligibility. |
| Specialist matching | CancerFax connects patients with oncologists experienced in checkpoint inhibitor immunotherapy across India, China, and other countries. |
| Global access support | For patients outside the USA/Europe, CancerFax identifies practical routes to access ipilimumab, including import pathways and specialist hospitals. |
| Second opinion guidance | If uncertain about ipilimumab vs alternatives, CancerFax arranges remote second opinions from leading immunotherapy specialists. |
| Cost navigation | CancerFax helps patients understand treatment costs, explore patient assistance programmes, and identify affordable sourcing options. |
| Side effect preparation | Education on recognizing immune-related adverse events, when to seek urgent care, and how to manage common toxicities supportively. |
Frequently asked questions about ipilimumab
Common questions from patients, caregivers, and healthcare partners
Ipilimumab (Yervoy) is an immunotherapy that blocks CTLA-4, a protein that normally suppresses the immune system. By removing this brake, ipilimumab allows your body's T cells to recognize and attack cancer cells. Unlike chemotherapy, which damages rapidly dividing cells broadly, ipilimumab works by unleashing your own immune system.
Ipilimumab often takes longer to show benefit than chemotherapy or targeted therapies. Patients may see initial response within 3 to 6 months, though some experience delayed responses or continued improvement over many months. Importantly, some patients achieve durable long-term cancer control after completing 4 doses of induction therapy.
Ipilimumab can cause immune-related adverse events (irAEs) where the activated immune system attacks normal tissues. Common side effects include fatigue, diarrhea, rash, and itching. Serious but manageable irAEs can affect the bowel (colitis), liver (hepatitis), lungs (pneumonitis), and hormone glands (endocrinopathy). Most irAEs respond well to corticosteroids and immunosuppressive management.
No. Ipilimumab is an immunotherapy, not chemotherapy. It is a monoclonal antibody that works by boosting the immune system rather than directly killing cancer cells. Because it works through immune activation rather than cell toxicity, the side effect profile is different from chemotherapy, with fewer effects like hair loss and nausea.
Yes. Ipilimumab is often combined with nivolumab, another checkpoint inhibitor, for improved outcomes in melanoma, kidney cancer, liver cancer, mesothelioma, lung cancer, and colorectal cancer. It can also be combined with chemotherapy in first-line lung cancer. Combinations improve response rates but also increase the risk of immune-related side effects.
If imaging shows cancer growth during or after ipilimumab, your oncologist will first rule out pseudoprogression (a temporary imaging pattern that can occur with immunotherapy). If true progression is confirmed, options include switching to targeted therapy, other immunotherapy combinations, chemotherapy, or clinical trials depending on cancer type and your overall health.
No. Ipilimumab is contraindicated in pregnancy and can cause serious foetal harm. Effective contraception is required during treatment. If you wish to become pregnant, discuss with your oncologist whether treatment-free remission or switching to a pregnancy-safer approach is possible. Never stop ipilimumab abruptly without specialist guidance.